Resverlogix
Late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses.
Launch date
Employees
Market cap
€11.1m
Enterprise valuation
€19m (Public information from Sep 2024)
Share price
CAD0.07 RVX.TO
Calgary Alberta (HQ)
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
EBITDA | (32.6m) | (38.9m) | (37.1m) | (74.2m) | (14.9m) | (11.7m) | (5.2m) |
Profit | (44.6m) | (54.6m) | (157m) | 118m | (24.8m) | (3.6m) | (16.7m) |
EV / EBITDA | -11.5x | -13.4x | -9.3x | -2.9x | -10.5x | -6.6x | -16.3x |
R&D budget | 28.9m | 35.4m | 31.1m | 15.8m | 4.5m | 5.5m | 3.2m |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | CAD70.7m | Late VC | |
N/A | N/A | IPO | |
$25.0m | Post IPO Equity | ||
N/A | $1.8m | Post IPO Equity | |
N/A | $1.6m | Post IPO Equity | |
N/A | $2.3m | Post IPO Equity | |
N/A | $10.0m | Post IPO Equity | |
N/A | N/A | Early VC | |
N/A | CAD21.8m | Post IPO Equity | |
N/A | $2.0m | Post IPO Equity | |
* |
| $6.0m | Post IPO Convertible |
Total Funding | €47.2m |
Related Content
Recent News about Resverlogix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.